Therapeutic targeting of PSMA might therefore induce this switch towards the ERK/MAPK pathway, which is nonetheless oncogenic, albeit weaker in its downstream effects on cancer cell escape mechanisms [100]. This evidence concerns the gene FOLH1 and cancer.